RxDoctor Payments Data

Chad Achenbach, MD

Infectious Disease · Chicago, ILNPI 1548278674

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,600 of the $4,159 with a category attached, or 86.6%. Viiv Healthcare Company accounts for 97.9% of it on its own, with 2 other manufacturers making up the rest.

$4,159in general payments, 2019–2025

Across 9 payments — averaging $462.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$4K
  • Janssen Products, LP$63
  • Gilead$25
$247,707in research payments, 2019–2025

Across 17 payments — averaging $14,571 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$145K
  • GSK$52K
  • Gilead$50K

What the payments were for

  • Consulting fees$3,60087%
  • Travel & lodging$39810%
  • Food & beverage$1333%
  • Education$291%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company6$4,071
Janssen Products, LP2$63
Gilead1$25

How this compares

$4,159 in reported general payments places this provider in the 85th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$17,908
Medicare patients
98
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala71$322,945
DovatoDolutegravir Sodium/Lamivudine65$190,557
GenvoyaElviteg/Cob/Emtri/Tenof Alafen33$143,930
DescovyEmtricitabine/Tenofov Alafenam39$96,535
TivicayDolutegravir Sodium34$84,640
PrezcobixDarunavir/Cobicistat20$69,116
JulucaDolutegravir/Rilpivirine16$62,953
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$58,454
IsentressRaltegravir Potassium26$56,994
Etravirine12$14,999
Emtricitabine12$5,700
Vancomycin Hcl13$2,451
ValacyclovirValacyclovir Hcl36$1,744
Testosterone Cypionate15$757
Nevirapine14$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$25$563,410143 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca$4,071$338,150115 claims
Janssen Products, LPSymtuza$63$58,45412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →